Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping
J S Schildcrout, J C Denny, E Bowton, W Gregg, J M Pulley, M A Basford, J D Cowan, H Xu, A H Ramirez, D C Crawford, M D Ritchie, J F Peterson, D R Masys, R A Wilke, D M Roden, J S Schildcrout, J C Denny, E Bowton, W Gregg, J M Pulley, M A Basford, J D Cowan, H Xu, A H Ramirez, D C Crawford, M D Ritchie, J F Peterson, D R Masys, R A Wilke, D M Roden
Abstract
Routine integration of genotype data into drug decision making could improve patient safety, particularly if many relevant genetic variants can be assayed simultaneously before prescribing the target drug. The frequency of opportunities for pharmacogenetic prescribing and the potential adverse events (AEs) mitigated are unknown. We examined the frequency with which 56 medications with known outcomes influenced by variant alleles were prescribed in a cohort of 52,942 medical home patients at Vanderbilt University Medical Center (VUMC). Within a 5-year window, we estimated that 64.8% (95% confidence interval (CI): 64.4-65.2%) of individuals were exposed to at least one medication with an established pharmacogenetic association. Using previously published results for six medications with severe, well-characterized, genetically linked AEs, we estimated that 383 events (95% CI, 212-552) could have been prevented with an effective preemptive genotyping program. Our results suggest that multiplexed, preemptive genotyping may represent an efficient alternative approach to current single-use ("reactive") methods and may also improve safety.
Conflict of interest statement
Conflicts of interest
The authors have no conflicts of interest to disclose.
Figures
Source: PubMed